Armaviscon 1% syringe 2 ml, 2 pcs.

Area of application – orthopedics, rheumatology, traumatology, surgery, sports medicine. Armaviscon is a joint synovial fluid protector. It is used against the background of degenerative changes of synovial cartilage surface to improve joint mobility, decrease pain syndrome, decrease inflammatory reactions and restore homeostasis in cartilage.

Properties and efficacy

The product has analgesic, corrective action on bone and cartilage metabolism. Armaviscon is a sterile viscous solution of sodium salt of hyaluronic acid (sodium hyaluronate) with a high degree of purification, with a high molecular weight.

Hyaluronic acid is an essential component of extracellular matrix, present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity of synovial fluid and is necessary for cartilage formation. In case of osteoarthritis there is a deficiency and qualitative changes of hyaluronic acid in synovial fluid and cartilage composition.

Intra-articular injection of hyaluronic acid leads to improvement of the functional state of the joint. When using Armaviscon in osteoarthritis of the knee joints improvement of clinical course is observed up to 6 months after application, anti-inflammatory and analgesic effect due to replenishment of the volume and restoration of viscosity and elasticity of synovial fluid that fills the joint cavity and acts as intra-articular lubricant.

It prevents friction of the articular surfaces, thus eliminating pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, ensures mobility and has cushioning properties (absorbs external blows protecting the joint components from damage).

The solution of sodium hyaluronate is distributed locally in the joint cavity, where it undergoes local transformation with its lubricating effect. Extraction or replacement of the product is not applicable, as it is inseparably mixed with the synovial fluid of the joint.

Indications

• Assists in increasing joint flexibility and relieves pain caused by degenerative-dystrophic or post-traumatic joint changes;
• Rehabilitation after arthroscopy;
• Treatment of patients with increased physical exertion and who regularly load the affected joint.

.

Active ingredient

Sodium hyaluronate

Composition

In 1 ml: sodium hyaluronate – 9-11 mg/ml (1%), sodium chloride – 8.50 mg/ml, sodium hydrophosphate dihydrate – 0.28 mg/ml, sodium di-hydrophosphate dihydrate – 0.044 mg/ml, water for injection – up to 1 ml.

Dynamic viscosity of the solution is > 100 mPa-s, osmolality – 250 – 350 mOsm/kg, pH – 6.5 – 7.5.

.

How to take, the dosage

Intra-articularly. The contents of one filled syringe, 2 ml (20 mg), should be injected into the knee joint once a week, for 5 injections using the standard technique described below. Typically a 1.5″ 21G needle is used for the knee joint, for other joints we recommend using an appropriate size needle (17G to 22G) depending on the joint.

The Insertion Procedure

The product must only be injected by trained medical personnel. The mode of administration to the hip and other joints is determined by the doctor individually, taking into account the severity of the degenerative or traumatic changes in the joint. It is recommended to perform injections into the hip and other joints under ultrasound or fluoroscopic control. It is recommended to warm the product to room temperature before use. The drug should be injected accurately into the joint cavity according to standard techniques, taking into account the anatomical features. Before administering the drug you should remove the effusion from the joint sac. The same needle once inserted prior to aspiration may be used to remove the effusion and administer the product.

The syringe containing the medication is then attached to the needle that has been freed from the syringe. The available amount of synovial fluid should be aspirated to confirm the needle is in the joint cavity prior to slow insertion. The rules of asepsis and antiseptics should be observed during the procedure. Injection into the joint cavity should be stopped if pain occurs during the injection. When injecting the needle, especially for injections into the hip joint, the use of local anesthesia is recommended. Avoid the introduction of air into the syringe.

The product should not be stored until completely used.

The duration of the therapeutic effect is up to 6 months. If necessary, it is possible to repeat the course of injections after consulting a doctor.

Interaction

Armaviscon should not be administered simultaneously with other intraarticular injections, due to lack of significant experience.

Disinfectants containing quaternary ammonium compounds should not be used, since hyaluronic acid precipitates in the presence of these substances.

Special Instructions

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and is carefully purified. However, the physician must consider the potential risks associated with the injection of any biological substances.

Extraarticular injection of Armaviskon into the joint capsule or synovial tissues is not allowed. This may cause local side effects. In the first 2 days after the procedure it is recommended not to overload the joint, especially avoid prolonged load. Armaviscon does not affect the ability to drive vehicles, engage in other potentially dangerous activities that require high concentration and quick psychomotor reactions. Patients with inflammatory diseases, in particular with Bechterew’s disease and rheumatoid arthritis, Armaviscon is not prescribed.

Not intended for children. Only for single use. The kit may include 2 single-use sterile injection needles to allow the doctor to choose the right needle size depending on the joint where the medicine will be injected. For safe use and disposal of used needles, follow national and regional rules and regulations.

Contraindications

– hypersensitivity to the components of the product;

– presence of infection or skin lesions in the area of injection;

– acute synovitis;

– childhood under 18 years of age (due to lack of clinical data).

Side effects

Mild soreness, edema, fever and redness in the injection area, and increased exudate in the joint cavity may occur. The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to unload the affected joint and apply ice.

In extremely rare cases, allergic reactions may occur.

Similarities

Ostenil, Fermatron, GOU-ON, Ostenil Plus, Fermatron Plus, Adant, Heimovis, Hyalripayer-10 Chondroreparant, Optinol, Hyalon Prosthesis